AEZS News and Press, Aeterna Zentaris Inc. From 05/17/21

Aeterna Zentaris (AEZS) has commenced the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), the most common motor neuron disease.The preclinical development pr...

- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of m acimorelin for the treatment of ALS CHARLESTON, S.C., Ma...

Aeterna Zentaris (AEZS) announces the commencement of its pivotal Phase 3 safety and efficacy study AEZS-130-P02 evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency (“CGHD”).The multicenter, open-label trial looks to investigate the ef...

– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on track to start...

– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET CHARLESTON, S.C., May 10, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical compa...

CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializi...

CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic pro...

– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline , intellectual property and portfolio of assets – P ivotal Phase 3 DET ECT (Study P02) safety and efficacy study evaluat...

Aeterna Zentaris (AEZS) announces the appointment of Michael Teifel as the company's Senior Vice President, Non-Clinical Development and Chief Scientific Officer.Teifel has over 20 years of experience and has held various positions with responsibility in fields of pharmacology, phar...

– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology CHARLESTON, S.C., May 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (&#x...